Hexa Reports Market Research Reports and Insightful Company Profiles Status Epilepticus Industry 2015 Market Share, Size, Industry Profile, Market Prize, Forecast and Overview Global Markets Direct's, 'Status Epilepticus - Pipeline Review, H2 2015', provides an overview of the Status Epilepticus's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Status Epilepticus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Status Epilepticus and special features on late-stage and discontinued projects. Browse Detail Report With TOC @ http://www.hexareports.com/report/status-epilepticus-pipeline- review-h2-2015/details Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Hexa Reports Market Research Reports and Insightful Company Profiles The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope The report provides a snapshot of the global therapeutic landscape of Primary Status Epilepticus The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Primary Status Epilepticusand enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects A review of the Primary Status Epilepticusproducts under development by companies and universities/research institutes based on information derived from company and industry specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Primary Status Epilepticuspipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Primary Status Epilepticus Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Primary Status Epilepticuspipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Hexa Reports Market Research Reports and Insightful Company Profiles Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Request A Sample copy of This Report @ http://www.hexareports.com/sample/46608 Table Of Content Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Status Epilepticus Overview 6 Therapeutics Development 7 Pipeline Products for Status Epilepticus - Overview 7 Pipeline Products for Status Epilepticus - Comparative Analysis 8 Status Epilepticus - Therapeutics under Development by Companies 9 Status Epilepticus - Therapeutics under Investigation by Universities/Institutes 10 Status Epilepticus - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Status Epilepticus - Products under Development by Companies 13 Status Epilepticus - Products under Investigation by Universities/Institutes 14 Status Epilepticus - Companies Involved in Therapeutics Development 15 Ligand Pharmaceuticals, Inc. 15 Sage Therapeutics 16 Status Epilepticus - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 25 ADD-405008 - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 AMPX-0079 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 fosphenytoin sodium - Drug Profile 27 Product Description 27
Hexa Reports Market Research Reports and Insightful Company Profiles Mechanism of Action 27 R&D Progress 27 SAGE-217 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 SAGE-547 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 SAGE-689 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 TG-4155 - Drug Profile 34 Product Description 34 Browse Full Report @http://www.hexareports.com/report/status-epilepticus-pipeline-review-h2- 2015/details About Us: Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives. Contact Information: Ryan Shaw Felton Office Plaza, 6265 Highway 9, Felton, California, 95018, United States Phone Number 1-800-489-3075 Email Us: email@example.com Our Website: http://www.hexareports.com/